天臣医疗（688013）披露2025年第三季度报告，10月23日股价上涨2.6%

Core Insights - Tianchen Medical (688013) reported a significant increase in revenue and net profit for the first three quarters of 2025, indicating strong financial performance driven by innovation and cost optimization [1][2]. Financial Performance - The company achieved operating revenue of 243,831,328.07 yuan, representing a year-on-year growth of 20.66% [1]. - Net profit attributable to shareholders reached 71,945,750.36 yuan, marking a substantial increase of 68.29% compared to the previous year [1]. - The net cash flow from operating activities was 63,784,159.86 yuan, up by 65.58% year-on-year [1]. Strategic Initiatives - Profit growth is attributed to the company's commitment to an innovation-driven strategy and a dual domestic and international market approach, leading to increased product volume and improved gross margin by 5.02 percentage points [1]. Asset and Equity Growth - Total assets amounted to 676,021,270.25 yuan, reflecting a growth of 6.09% from the end of the previous year [1]. - Shareholders' equity attributable to the parent company was 599,615,312.18 yuan, which is a 3.13% increase from the previous year-end [1]. Shareholder Information - As of the report date, the total number of ordinary shareholders was 4,624, with the top two shareholders, Chen Wangyu and Chen Wangdong, holding 25.85% and 25.79% of the shares, respectively, acting as controlling shareholders [2].